Evaluating the efficacy of the Kyoto classification of gastritis in diagnosing Helicobacter pylori infection

Korzheva I.Yu.; Laktyun’kina E.N.; Kozyr’ L.V.; Syzrantsev A.Yu.

doi:https://doi.org/10.17116/dokgastro20251401129

Close metadata

MATERIAL AND METHODS

A retrospective case-control study involving 329 patients (206 women and 123 men) with a median age of 49 years (range 17—85 years) who underwent examination from 2020 to 2024. High-resolution white-light endoscopy and narrow-band imaging modes was used. H. pylori infection was diagnosed using histological examination and a rapid urease test. Statistical analysis included logistic regression and ROC analysis.

RESULTS

Statistically significant endoscopic features of infected mucosa included diffuse hyperemia (OR=255; 95% CI 91.3—937.3), enlarged folds (OR=10.7; 95% CI 3.190—35.906), granularity (OR=17.3; 95% CI 2.3—131.8), and mucosal edema (OR=15.1; 95% CI 8.663—26.445). Non-infected mucosa was characterized by regular arrangement of collecting venules (OR=0.018; 95% CI 0.006—0.060) and their recurrence (OR=0.074; 95% CI 0.035—0.156). The predictive model showed a sensitivity of 92.9% and specificity of 93.2%.

CONCLUSION

The Kyoto classification of gastritis has proven to be a simple and effective tool for endoscopic diagnosis of H. pylori-associated gastritis. The study results offer new opportunities for clinical practice, facilitating early diagnosis and reducing gastric cancer incidence.

Keywords:

Helicobacter pylori

gastritis

endoscopy

Kyoto classification

atrophy

Authors:

Korzheva I.Yu.

Russian Medical Academy for Continuous Professional Education;
Botkin Moscow Multidisciplinary Scientific and Clinical Center

ORCID: 0000-0002-5984-5660

Laktyun’kina E.N.

Russian Medical Academy for Continuous Professional Education;
Veresaev Moscow City Clinical Hospital

ORCID: 0000-0002-5920-5380

Kozyr’ L.V.

Pirogov Russian National Research Medical University

ORCID: 0009-0002-5254-5873

Syzrantsev A.Yu.

Botkin Moscow Multidisciplinary Scientific and Clinical Center

ORCID: 0009-0001-8153-4412

Received:

09.10.2024

Accepted:

19.11.2024

Close metadata

References:

Bordin D, Morozov S, Plavnik R, Bakulina N, Voynovan I, Skibo I, Isakov V, Bakulin I, Andreev D, Maev I. Helicobacter pylori infection prevalence in ambulatory settings in 2017-2019 in RUSSIA: The data of real-world national multicenter trial. Helicobacter. 2022;27(5):e12924. https://doi.org/10.1111/hel.12924
Ivashkin VT, Maev IV, Lapina TL, Fedorov ED, Sheptulin AA, Trukhmanov AS, Kononov AV, Abdulkhakov RA, Alexeeva OP, Alekseenko SA, Andreev DN, Baranskaya EK, Dekhnich NN, Klyaritskaya IL, Kozlov RS, Kogan EA, Korolev MP, Korochanskaya NV, Kurilovich SA, Livsan MA, Osipenko MF, Pavlov PV, Pirogov SS, Sarsenbaeva AS, Simanenkov VI, Tertychny AS, Tkachev AV, Uspensky YuP, Khlynov IB, Tsukanov VV. Clinical Recommendations of Russian Gastroenterological Association and RENDO Endoscopic Society on Diagnosis and Treatment of Gastritis and Duodenitis. Rossijskij zhurnal gastroe`nterologii, gepatologii, koloproktologii. 2021;31(4):70-99. (In Russ.). https://doi.org/10.22416/1382-4376-2021-31-4-70-99
Gastrit i duodenit. Klinicheskie rekomendatsii. 2024. (In Russ.). Accessed January 29, 2025. https://cr.minzdrav.gov.ru/preview-cr/708_2
Yoshii S, Mabe K, Watano K, Ohno M, Matsumoto M, Ono S, Kudo T, Nojima M, Kato M, Sakamoto N. Validity of endoscopic features for the diagnosis of Helicobacter pylori infection status based on the Kyoto classification of gastritis. Digestive Endoscopy. 2020;32(1):74-83. https://doi.org/10.1111/den.13486
Besova NS, Kalinin AE, Nered SN, Triakin AA, Gamaiunov SV, Kozlov NA, Stilidi IS, Karachun AM, Kononets PV, Malikhova OA, Riabov AB, Khomiakov VM, Fedenko AA, Bolotina LV, Falaleeva NA, Nevol’skikh AA, Ivanov SA, Khailova ZV, Gevorkian TG, Butenko AV, Gil’mutdinova IR, Eremushkin MA, Ivanova GE, Kondrat’eva KO, Konchugova TV, Krutov AA, Obukhova OA, Semiglazova TI, Filonenko EV, Khulamkhanova MM, Romanov AI. Gastric cancer: Russian clinical guidelines. Journal of Modern Oncology. 2021;23(4):541-571. (In Russ.). https://doi.org/10.26442/18151434.2021.4.201239
Zlokachestvennye novoobrazovaniya v Rossii v 2021 godu (zabolevaemost’ i smertnost’). Kaprin AD, Starinsky VV, Shakhzadova AO, eds. M.: MNIOI im. P.A. Gertsena — filial FGBU «NMITs radiologii» Minzdrava Rossii; 2022. (In Russ.).
Glover B, Teare J, Patel N. A systematic review of the role of non-magnified endoscopy for the assessment of H. pylori infection. Endoscopy International Open. 2020;8(2):E105-E114. https://doi.org/10.1055/a-0999-5252
Sakitani K, Nishizawa T, Arita M, Yoshida S, Kataoka Y, Ohki D, Yamashita H, Isomura Y, Toyoshima A, Watanabe H, Iizuka T, Saito Y, Fujisaki J, Yahagi N, Koike K, Toyoshima O. Early detection of gastric cancer after Helicobacter pylori eradication due to endoscopic surveillance. Helicobacter. 2018;23(4):e12503. https://doi.org/10.1111/hel.12503
Dohi O, Majima A, Naito Y, Yoshida T, Ishida T, Azuma Y, Kitae H, Matsumura S, Mizuno N, Yoshida N, Kamada K, Itoh Y. Can image-enhanced endoscopy improve the diagnosis of Kyoto classification of gastritis in the clinical setting? Digestive Endoscopy. 2020;32(2):191-203. https://doi.org/10.1111/den.13540
Zhao J, Xu S, Gao Y, Lei Y, Zou B, Zhou M, Chang D, Dong L, Qin B. Accuracy of endoscopic diagnosis of Helicobacter pylori based on the Kyoto classification of gastritis: a multicenter study. Frontiers in Oncology. 2020;10:599218. https://doi.org/10.3389/fonc.2020.599218
Wang K, Zhao J, Jin H, Meng L, Fan Y, Zhou Y, Ye C, Li M, Ma P, Zhu L, Ye Y, Lyu B. Establishment of a modified Kyoto classification scoring model and its significance in the diagnosis of Helicobacter pylori current infection. Gastrointestinal Endoscopy. 2023;97(4):684-693. https://doi.org/10.1016/j.gie.2022.11.008
Emura F, Sharma P, Arantes V, Cerisoli C, Parra-Blanco A, Sumiyama K, Araya R, Sobrino S, Chiu P, Matsuda K, Gonzalez R, Fujishiro M, Tajiri H. Principles and practice to facilitate complete photodocumentation of the upper gastrointestinal tract: World Endoscopy Organization position statement. Digestive Endoscopy. 2020;32(2):168-179. https://doi.org/10.1111/den.13530
Haruma K, Kato M, Inoue K, Murakami K, Kamada T. Kyoto Classification of Gastritis. Tokyo: Nihon Medical Center; 2017.
Yagi K, Nakamura A, Sekine A. Magnifying endoscopic findings of gastritis. Gastroenterological Endoscopy. 2007;49(5):1251-1257.
Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;1(03):87-97. https://doi.org/10.1055/s-0028-1098086
Bordin DS, Shengelia MI, Ivanova VA, Voynovan IN. Helicobacter pylori: clinical significance and diagnostic principles. Infektsionnye bolezni. Novosti. Mneniya. Obuchenie. 2022;11(1):119-129. https://doi.org/10.33029/2305-3496-2022-11-1-119-129
Panarese A, Saito Y, Zagari RM. Kyoto classification of gastritis, virtual chromoendoscopy and artificial intelligence: Where are we going? What do we need? Artificial Intelligence in Gastrointestinal Endoscopy. 2023;4(1):1-11. https://doi.org/10.37126/aige.v4.i1.1
Uchiyama K, Ida K, Okuda J, Asai Y, Ohyama Y, Kuroda M, Matsumoto N, Takami T, Ogawa T, Takaori K. Correlations of hemoglobin index (IHb) of gastric mucosa with Helicobacter pylori (H. pylori) infection and inflammation of gastric mucosa. Scandinavian Journal of Gastroenterology. 2004;39(11):1054-1060. https://doi.org/10.1080/00365520410009645
Yagi K, Honda H, Yang JM, Nakagawa S. Magnifying endoscopy in gastritis of the corpus. Endoscopy. 2005;37(7):660-666. https://doi.org/10.1055/s-2005-861423

Kurokawa Y, Honma Y, Sawaki A, Naito Y, Iwagami S, Komatsu Y, Takahashi T, Nishida T, Doi T. Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial. Annals of Oncology. 2022;33(9):959-967. https://doi.org/10.1016/j.annonc.2022.05.518

Du CY, Zhou Y, Song C, Wang YP, Jie ZG, He YL, Liang XB, Cao H, Yan ZS, Shi YQ. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: A prospective randomised trial in China. European Journal of Cancer. 2014;50(10):1772-1778. https://doi.org/10.1016/j.ejca.2014.03.280

McAuliffe JC, Hunt KK, Lazar AJ, Choi H, Qiao W, Thall P, Pollock RE, Benjamin RS, Trent JC. A Randomized, Phase II Study of Preoperative plus Postoperative Imatinib in GIST: Evidence of Rapid Radiographic Response and Temporal Induction of Tumor Cell Apoptosis. Annals of Surgical Oncology. 2009;16(4):910-919. https://doi.org/10.1245/s10434-008-0177-7

Corless CL, Ballman KV, Antonescu C, Blanke CD, Blackstein ME, Demetri GD, von Mehren M, Maki RG, Pisters PW, DeMatteo RP. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001. Journal of Clinical Oncology. 2010;28(15 Suppl):10006-10006. https://doi.org/10.1200/jco.2010.28.15_suppl.10006

Cousin S. A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE). Accessed August 20, 2024. https://clinicaltrials.gov/study/NCT03475953#more-information

Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib. Accessed August 20, 2024. https://clinicaltrials.gov/study/NCT0440922

Cogent Biosciences. (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors. Accessed August 20, 2024. https://clinicaltrials.gov/ct2/show/NCT05208047

Matsumoto S, Takayama T, Wakatsuki K, Enomoto K, Tanaka T, Migita K, Takano M, Nakajima Y. An esophageal gastrointestinal stromal tumor with regional lymph node metastasis. Esophagus. 2010;7(2):115-118. https://doi.org/10.1007/s10388-010-0231-y

Koyanagi K, Nakagawa M, Ozawa S, Nagase T, Seishima R, Kanai T. Thoracoscopic enucleation for small-sized gastrointestinal stromal tumor of the esophagus: report of two cases. Esophagus. 2010;7(4):219-224. https://doi.org/10.1007/s10388-010-0243-7

Masuda T, Toh Y, Kabashima A, Aoki Y, Harimoto N, Ito S, Taomoto J, Ikeda O, Ohga T, Adachi E, Sakaguchi Y, Hirahashi M, Nishiyama K, Okamura T. Overt lymph node metastases from a gastrointestinal stromal tumor of the esophagus. Journal of Thoracic and Cardiovascular Surgery. 2007;134(3):810-811. https://doi.org/10.1016/j.jtcvs.2007.06.002

Kobayashi H, Kiguchi G, Miki A, Uryuhara K, Okada N, Kaihara S, Imai Y, Hosotani R. A case report of giant esophageal gastrointestinal stromal tumor surgically resected after preoperative imatinib treatment. Esophagus. 2011;8(2):119-124. https://doi.org/10.1007/s10388-011-0264-x

Sato H, Kanda T, Hirota S, Bamba T, Sakamoto K, Kosugi SI, Matsuki A, Mashima Y, Watanabe G, Hatakeyama K. Surgical resection of gastrointestinal stromal tumor of esophagus following preoperative imatinib treatment: a case report. Esophagus. 2010;7(1):65-69. https://doi.org/10.1007/s10388-009-0217-9

Miettinen M, Sobin LH, Lasota J. Gastrointestinal Stromal Tumors of the Stomach. American Journal of Surgical Pathology. 2005;29(1):52-68. https://doi.org/10.1097/01.pas.0000146010.92933

Luo Y, Wu Y, Chang X, Huang B, Luo D, Zhang J, Zhang P, Shi H, Fan J, Nie X. Identification of a novel FGFR2-KIAA1217 fusion in esophageal gastrointestinal stromal tumours: A case report. Frontiers in Oncology. 2022;12. https://doi.org/10.3389/fonc.2022.884814

Haller F, Moskalev EA, Faucz FR, Barthelmeß S, Wiemann S, Bieg M, Assie G, Bertherat J, Schaefer IM, Otto C, Rattenberry E, Maher ER, Ströbel P, Werner M, Carney JA, Hartmann A, Stratakis CA, Agaimy A. Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad. Endocrine-Related Cancer. 2014;21(4):567-577. https://doi.org/10.1530/ERC-14-0254

Zhang L, Smyrk TC, Young WF, Stratakis CA, Carney JA. Gastric Stromal Tumors in Carney Triad Are Different Clinically, Pathologically, and Behaviorally From Sporadic Gastric Gastrointestinal Stromal Tumors: Findings in 104 Cases. American Journal of Surgical Pathology. 2010;34(1):53-64. https://doi.org/10.1097/PAS.0b013e3181c20f4f

Ricci R, Martini M, Cenci T, Carbone A, Lanza P, Biondi A, Rindi G, Cassano A, Larghi A, Persiani R, Larocca LM. PDGFRA-mutant syndrome. Modern Pathology. 2015;28(7):954-964. https://doi.org/10.1038/modpathol.2015.56

Arita A, Takahashi T, Nakajima K, Kurokawa Y, Hirota S, Nishida T, Yamashita K, Saito T, Tanaka K, Makino T, Yamasaki M, Kawai K, Motoyama Y, Morii E, Eguchi H, Doki Y. Surgery for multiple gastric gastrointestinal stromal tumors and large esophageal diverticulum related to germline mutation of the KIT gene: a case report. Surgical Case Reports. 2023;9(1):183. https://doi.org/10.1186/s40792-023-01766-w

Bachet JB, Landi B, Laurent-Puig P, Italiano A, Le Cesne A, Lévy P, Safar V, Duffaud F, Blay JY, Emile JF. Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13. European Journal of Cancer. 2013;49(11):2531-2541. https://doi.org/10.1016/j.ejca.2013.04.005

Ohshima K, Fujiya K, Nagashima T, Ohnami S, Hatakeyama K, Urakami K, Naruoka A, Watanabe Y, Moromizato S, Shimoda Y, Ohnami S, Serizawa M, Akiyama Y, Kusuhara M, Mochizuki T, Sugino T, Shiomi A, Tsubosa Y, Uesaka K, Terashima M, Yamaguchi K. Driver gene alterations and activated signaling pathways toward malignant progression of gastrointestinal stromal tumors. Cancer Science. 2019;110(12):3821-3833. https://doi.org/10.1111/cas.14202

Joensuu H, Eriksson M, Hall KS, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Ballman KV, Leinonen M, DeMatteo RP, Reichardt P. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. Cancer. 2014;120(15):2325-2333. https://doi.org/10.1002/cncr.28669

Rubió-Casadevall J, Borràs JL, Carmona-García MC, Ameijide A, Gonzalez-Vidal A, Ortiz MR, Bosch R, Riu F, Parada D, Martí E, Miró J, Sirvent JJ, Galceran J, Marcos-Gragera R. Correlation between mutational status and survival and second cancer risk assessment in patients with gastrointestinal stromal tumors: a population-based study. World Journal of Surgical Oncology. 2015;13(1):47. https://doi.org/10.1186/s12957-015-0474-0

Joensuu H, Rutkowski P, Nishida T, Steigen SE, Brabec P, Plank L, Nilsson B, Braconi C, Bordoni A, Magnusson MK, Sufliarsky J, Federico M, Jonasson JG, Hostein I, Bringuier PP, Emile JF. KIT and PDGFRA Mutations and the Risk of GI Stromal Tumor Recurrence. Journal of Clinical Oncology. 2015;33(6):634-642. https://doi.org/10.1200/JCO.2014.57.4970

Park JW, Cho CH, Jeong DS, Chae HD. Role of 18F-fluoro-2-deoxyglucose Positron Emission Tomography in Gastric GIST: Predicting Malignant Potential Pre-operatively. Journal of Gastric Cancer. 2011;11(3):173-179. https://doi.org/10.5230/jgc.2011.11.3.173

Dendy M, Johnson K, Boffa DJ. Spectrum of FDG uptake in large (>10 cm) esophageal leiomyomas. Journal of Thoracic Disease. 2015;7(12):E648-E651. https://doi.org/10.3978/j.issn.2072-1439.2015.11.64

Săftoiu A. Endoscopic ultrasound-guided fine needle aspiration biopsy for the molecular diagnosis of gastrointestinal stromal tumors: shifting treatment options. Journal of Gastrointestinal and Liver Diseases. 2008;17(2):131-133.

Lott S, Schmieder M, Mayer B, Henne-Bruns D, Knippschild U, Agaimy A, Schwab M, Kramer K. Gastrointestinal stromal tumors of the esophagus: evaluation of a pooled case series regarding clinicopathological features and clinical outcome. American Journal of Cancer Research. 2015;5(1):333-343.

Stelow EB, Stanley MW, Lai R, Mallery S. Endoscopic Ultrasound-Guided Fine-Needle Aspiration Findings of Gastrointestinal Leiomyomas and Gastrointestinal Stromal Tumors. American Journal of Clinical Pathology. 2003;119(5):703-708. https://doi.org/10.1309/UWUV-Q001-0D9W-0HPN

Nemeth K, Williams C, Rashid M, Robinson M, Rasheed A. Oesophageal GIST—A rare breed case report and review of the literature. International Journal of Surgery Case Reports. 2015;10: 256-259. https://doi.org/10.1016/j.ijscr.2015.02.023

Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology. 2008;53(3):245-266. https://doi.org/10.1111/j.1365-2559.2008.02977.x

Gold JS, Gönen M, Gutiérrez A, Broto JM, García-del-Muro X, Smyrk TC, Maki RG, Singer S, Brennan MF, Antonescu CR, Donohue JH, DeMatteo RP. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. The Lancet Oncology. 2009;10(11):1045-1052. https://doi.org/10.1016/S1470-2045(09)70242-6

Wozniak A, Rutkowski P, Piskorz A, Ciwoniuk M, Osuch C, Bylina E, Sygut J, Chosia M, Rys J, Urbanczyk K, Kruszewski W, Sowa P, Siedlecki J, Debiec-Rychter M, Limon J; Polish Clinical GIST Registry. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. Annals of Oncology. 2012;23(2):353-360. https://doi.org/10.1093/annonc/mdr127

Yamamoto H, Ebihara Y, Tanaka K, Matsui A, Nakanishi Y, Asano T, Noji T, Kurashima Y, Murakami S, Nakamura T, Tsuchikawa T, Okamura K, Shichinohe T, Hirano S. Robot-assisted thoracoscopic esophagectomy for gastrointestinal stromal tumor of the esophagus: A case report. International Journal of Surgery Case Reports. 2021;86:106335. https://doi.org/10.1016/j.ijscr.2021.106335

Marqueen KE, Moshier E, Buckstein M, Ang C. Neoadjuvant therapy for gastrointestinal stromal tumors: A propensity score‐weighted analysis. International Journal of Cancer. 2021;149(1):177-185. https://doi.org/10.1002/ijc.33536

Wang D, Zhang Q, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M, Eisenberg BL. Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132. Annals of Surgical Oncology. 2012;19(4):1074-1080. https://doi.org/10.1245/s10434-011-2190-5

Nishida T, Kanda T, Nishitani A, Takahashi T, Nakajima K, Ishikawa T, Hirota S. Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib‐resistant gastrointestinal stromal tumor. Cancer Science. 2008;99(4):799-804. https://doi.org/10.1111/j.1349-7006.2008.00727.x

Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, Brennan MF, Maki RG, DeMatteo RP. Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation. Clinical Cancer Research. 2005;11(11):4182-4190. https://doi.org/10.1158/1078-0432.CCR-04-2245

See full prescribing information for VITRAKVI. Accessed September 10, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf

US Food and Drug Administration. Prescribing information — Rozlytrek. Accessed September 10, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf

Yebra M, Bhargava S, Kumar A, Burgoyne AM, Tang CM, Yoon H, Banerjee S, Aguilera J, Cordes T, Sheth V, Noh S, Ustoy R, Li S, Advani SJ, Corless CL, Heinrich MC, Kurzrock R, Lippman SM, Fanta PT, Harismendy O, Metallo C, Sicklick JK. Establishment of Patient-Derived Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response. Clinical Cancer Research. 2022;28(1):187-200. https://doi.org/10.1158/1078-0432.CCR-21-2092

Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST). Accessed September 10, 2024. https://clinicaltrials.gov/study/NCT03556384

Dhillon S. Ripretinib: First Approval. Drugs. 2020;80(11):1133-1138. https://doi.org/10.1007/s40265-020-01348-2

See full prescribing information for QINLOCK. Accessed September 10, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf

US Food and Drug Administration. FDA approves avapritinib for gastrointestinal stromal tumor with a rare mutation. Accessed September 10, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation

Chi P, Qin LX, Nguyen B, Kelly CM, D’Angelo SP, Dickson MA, Gounder MM, Keohan ML, Movva S, Nacev BA, Rosenbaum E, Thornton KA, Crago AM, Yoon S, Ulaner G, Yeh R, Martindale M, Phelan HT, Biniakewitz MD, Warda S, Lee CJ, Berger MF, Schultz ND, Singer S, Hwang S, Chen Y, Antonescu CR, Tap WD. Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. Journal of Clinical Oncology. 2022;40(9):997-1008. https://doi.org/10.1200/JCO.21.02029

US National Library of Medicine. A study of pimitespib in combination with imatinib in patients with GIST (CHAPTER-GIST-101). Accessed September 10, 2024. https://www.clinicaltrials.gov/ct2/show/NCT05245968

Joensuu H, Blay JY, Comandone A, Martin-Broto J, Fumagalli E, Grignani G, Del Muro XG, Adenis A, Valverde C, Pousa AL, Bouché O, Italiano A, Bauer S, Barone C, Weiss C, Crippa S, Camozzi M, Castellana R, Le Cesne A. Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib. British Journal of Cancer. 2017;117(9):1278-1285. https://doi.org/10.1038/bjc.2017.290

Adis insight. Gastrointestinal stromal tumours. Accessed September 10, 2024. https://adisinsight.springer.com/drugs/800063657

US National Library of Medicine. A phase I/II study of regorafenib plus avelumab in solid tumors (REGOMUNE). Accessed September 10, 2024. https://clinicaltrials.gov/ct2/show/NCT03475953

US National Library of Medicine. PDR001 plus imatinib for metastatic or unresectable GIST. Accessed September 10, 2024. https://clinicaltrials.gov/ct2/show/NCT03609424

Call J, Walentas C, Eickhoff JC, Scherzer N. Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry. BMC Cancer. 2012;12(1):90. https://doi.org/10.1186/1471-2407-12-90

Miettinen M, Lasota J. Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Seminars in Diagnostic Pathology. 2006;23(2):70-83. https://doi.org/10.1053/j.semdp.2006.09.001

IJzerman NS, van Werkhoven E, Mohammadi M, Hollander DD, Bleckman RF, Reyners AKL, Desar IME, Gelderblom H, Grünhagen DJ, Mathijssen RHJ, Steeghs N, van der Graaf WTA. Sex differences in patients with gastrointestinal stromal tumours: do they exist and does it affect survival? ESMO Open. 2022;7(6):100649. https://doi.org/10.1016/j.esmoop.2022.100649

Volchenko NS, Mamontov AS, Goeva NS. Rare esophageal tumors. Onkologiya. P.A. Herzen Journal of Oncology. 2019;8(6):453. https://doi.org/10.17116/onkolog20198061453

Cohen C, Pop D, Icard P, Berthet JP, Venissac N, Mouroux J. Is There a Place for Thoracoscopic Enucleation of Esophageal Gastrointestinal Stromal Tumors? The Thoracic and Cardiovascular Surgeon. 2019;67(07):585-588. https://doi.org/10.1055/s-0038-1670662

Keung EZ, Raut CP. Management of Gastrointestinal Stromal Tumors. Surgical Clinics of North America. 2017;97(2):437-452. https://doi.org/10.1016/j.suc.2016.12.001

Gronchi A, Raut CP. The Combination of Surgery and Imatinib in GIST: A Reality for Localized Tumors at High Risk, an Open Issue for Metastatic Ones. Annals of Surgical Oncology. 2012;19(4): 1051-1055. https://doi.org/10.1245/s10434-011-2191-4

Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, Fletcher CD, Demetri GD, Bertagnolli MM. Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment With Targeted Systemic Therapy Using Kinase Inhibitors. Journal of Clinical Oncology. 2006;24(15):2325-2331. https://doi.org/10.1200/JCO.2005.05.3439

Blackstein ME, Blay JY, Corless C, Driman DK, Riddell R, Soulières D, Swallow CJ, Verma S; Canadian Advisory Committee on GIST. Gastrointestinal Stromal Tumours: Consensus Statement on Diagnosis and Treatment. Canadian Journal of Gastroenterology. 2006;20(3):157-163. https://doi.org/10.1155/2006/434761

DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR. Results of Tyrosine Kinase Inhibitor Therapy Followed by Surgical Resection for Metastatic Gastrointestinal Stromal Tumor. Annals of Surgery. 2007;245(3):347-352. https://doi.org/10.1097/01.sla.0000236630.93587.59

Klug LR, Khosroyani HM, Kent JD, Heinrich MC. New treatment strategies for advanced-stage gastrointestinal stromal tumours. Nature Reviews Clinical Oncology. 2022;19(5):328-341. https://doi.org/10.1038/s41571-022-00606-4

A phase 1, multicenter, open-label, first-in-human study of DS-6157a in patients (pts) with advanced gastrointestinal stromal tumor (GIST). Accessed September 10, 2024. https://meetings.asco.org/abstracts-presentations/208008

DS-6157a in Participants with Advanced Gastrointestinal Stromal Tumor (GIST). Accessed September 10, 2024. https://clinicaltrials.gov/ct2/show/NCT04276415